Atara Biotherapeutics (ATRA) Stock Price, News & Analysis

Company Overview

Atara Biotherapeutics, Inc. is a biotechnology company focused on developing T-cell immunotherapies for cancer and serious diseases associated with viral infections. The company’s approach uses allogeneic, or donor-derived, T cells that are selected or engineered to recognize disease-related targets, with the goal of providing off-the-shelf treatment options.

Atara’s lead product, Ebvallo (tabelecleucel), is an allogeneic T-cell immunotherapy designed to treat Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD) in certain patients who have received a solid-organ or hematopoietic-cell transplant. Ebvallo received marketing authorization in the European Union and is commercialized in international markets through collaboration arrangements. The company has also developed investigational programs in areas including multiple sclerosis and oncology, although its pipeline has changed over time as programs have advanced or been discontinued.

Founded in 2012 and headquartered in Thousand Oaks, California, Atara has focused primarily on serving patients in the United States and international markets through regulatory submissions, partnerships and commercialization agreements. Pascal Touchon has served as the company’s president and chief executive officer. As with other biotechnology companies, Atara’s product portfolio and corporate structure may change as clinical, regulatory and commercial activities progress.

Key Stats

• Today's Range: $9.20 to $9.66
• 50-Day Range: $8.05 to $10.23
• 52-Week Range: $3.92 to $19.15
• Volume: 11,532 shs
• Average Volume: 608,036 shs
• Market Capitalization: $96.99 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.50
• Consensus Rating: Moderate Buy

Atara Biotherapeutics Stock Analysis - MarketRank™

Atara Biotherapeutics scored higher than 41% of companies evaluated by MarketBeat, and ranked 690th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.8 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Atara Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 strong buy rating, 1 buy rating, 1 hold rating, and 1 sell rating.

Upside/Downside

The consensus price target for Atara Biotherapeutics is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Atara Biotherapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Atara Biotherapeutics are expected to grow in the coming year, from ($0.22) to $1.38 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Atara Biotherapeutics is -7.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Atara Biotherapeutics is -7.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.45% of the float of Atara Biotherapeutics has been sold short.

Short Interest Ratio / Days to Cover

Atara Biotherapeutics has a short interest ratio ("days to cover") of 8.11.

Change versus previous month

Short interest in Atara Biotherapeutics has recently decreased by 20.40%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Atara Biotherapeutics does not currently pay a dividend.

Dividend Growth

Atara Biotherapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 1.07

News Sentiment

Atara Biotherapeutics has a news sentiment score of 1.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Atara Biotherapeutics this week, compared to 5 articles on an average week.

Company Ownership

• Score: 4.3 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $959,093.00 in company stock, which represents 1.0261% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Atara Biotherapeutics insiders have bought 2,344.91% more of their company's stock than they have sold. Specifically, they have bought $999,994.00 in company stock and sold $40,901.00 in company stock.

Percentage Held by Insiders

41.20% of the stock of Atara Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

70.90% of the stock of Atara Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 10/14/2026
• Next Earnings (Estimated): 10/29/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ATRA
• CIK: 1604464
• Web: www.atarabio.com
• Phone: (805) 623-4211
• Fax: N/A
• Employees: 10
• Year Founded: 2012

Price Target and Rating

• Average Price Target for Atara Biotherapeutics: $9.50
• High Price Target: $13.00
• Low Price Target: $6.00
• Potential Upside/Downside: +1.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.18)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $32.69 million
• Net Margins: -269.42%
• Pretax Margin: -268.95%
• Return on Equity: N/A
• Return on Assets: -73.01%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.98
• Quick Ratio: 1.98

Sales & Book Value

• Annual Sales: $120.77 million
• Price / Sales: 0.78
• Cash Flow: $4.84 per share
• Price / Cash Flow: 1.93
• Book Value: ($5.34) per share
• Price / Book: -1.75

Miscellaneous

• Outstanding Shares: 10,040,000
• Free Float: 5,902,000
• Market Cap: $93.77 million
• Optionable: No Data
• Beta: 0.21